313: Biotech layoffs, founder-focused VC, & a big pharma exit
The Readout Loud
00:00
Pfizer's Obesity Program and Drug Announcement
Exploring Pfizer's challenges and plans in the obesity space, including the announcement of a new version of Danu-Glip-Ron, sparking speculation and skepticism among analysts. The chapter delves into Pfizer's collaboration with Flagship Pioneering and the search for a suitable executive leader amidst discussions on drug efficacy and decision-making processes.
Transcript
Play full episode
